Skip to main content

Main menu

  • Home
  • Articles
    • Current Issue
    • Next in The JI
    • Archive
    • Brief Reviews
      • Neuroimmunology: To Sense and Protect
    • Pillars of Immunology
    • Translating Immunology
    • Most Read
    • Top Downloads
    • Annual Meeting Abstracts
  • COVID-19/SARS/MERS Articles
  • Info
    • About the Journal
    • For Authors
    • Journal Policies
    • Influence Statement
    • For Advertisers
  • Editors
  • Submit
    • Submit a Manuscript
    • Instructions for Authors
    • Journal Policies
  • Subscribe
    • Journal Subscriptions
    • Email Alerts
    • RSS Feeds
    • ImmunoCasts
  • More
    • Most Read
    • Most Cited
    • ImmunoCasts
    • AAI Disclaimer
    • Feedback
    • Help
    • Accessibility Statement
  • Other Publications
    • American Association of Immunologists
    • ImmunoHorizons

User menu

  • Subscribe
  • Log in

Search

  • Advanced search
The Journal of Immunology
  • Other Publications
    • American Association of Immunologists
    • ImmunoHorizons
  • Subscribe
  • Log in
The Journal of Immunology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Next in The JI
    • Archive
    • Brief Reviews
    • Pillars of Immunology
    • Translating Immunology
    • Most Read
    • Top Downloads
    • Annual Meeting Abstracts
  • COVID-19/SARS/MERS Articles
  • Info
    • About the Journal
    • For Authors
    • Journal Policies
    • Influence Statement
    • For Advertisers
  • Editors
  • Submit
    • Submit a Manuscript
    • Instructions for Authors
    • Journal Policies
  • Subscribe
    • Journal Subscriptions
    • Email Alerts
    • RSS Feeds
    • ImmunoCasts
  • More
    • Most Read
    • Most Cited
    • ImmunoCasts
    • AAI Disclaimer
    • Feedback
    • Help
    • Accessibility Statement
  • Follow The Journal of Immunology on Twitter
  • Follow The Journal of Immunology on RSS

Cutting Edge: IL-1α Is a Crucial Danger Signal Triggering Acute Myocardial Inflammation during Myocardial Infarction

Jérôme Lugrin, Roumen Parapanov, Nathalie Rosenblatt-Velin, Stéphanie Rignault-Clerc, François Feihl, Bernard Waeber, Olivier Müller, Catherine Vergely, Marianne Zeller, Aubry Tardivel, Pascal Schneider, Pal Pacher and Lucas Liaudet
J Immunol January 15, 2015, 194 (2) 499-503; DOI: https://doi.org/10.4049/jimmunol.1401948
Jérôme Lugrin
*Department of Intensive Care Medicine, University Hospital Medical Center, University of Lausanne, 1011 Lausanne, Switzerland;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Roumen Parapanov
*Department of Intensive Care Medicine, University Hospital Medical Center, University of Lausanne, 1011 Lausanne, Switzerland;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nathalie Rosenblatt-Velin
†Department of Clinical Pathophysiology, University Hospital Medical Center, University of Lausanne, 1011 Lausanne, Switzerland;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stéphanie Rignault-Clerc
†Department of Clinical Pathophysiology, University Hospital Medical Center, University of Lausanne, 1011 Lausanne, Switzerland;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
François Feihl
†Department of Clinical Pathophysiology, University Hospital Medical Center, University of Lausanne, 1011 Lausanne, Switzerland;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bernard Waeber
†Department of Clinical Pathophysiology, University Hospital Medical Center, University of Lausanne, 1011 Lausanne, Switzerland;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Olivier Müller
‡Department of Cardiology, University Hospital Medical Center, University of Lausanne, 1011 Lausanne, Switzerland;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Catherine Vergely
§Laboratoire de Physiopathologie et Pharmacologie Cardio-Métaboliques, INSERM Unité Mixte de Recherche 866, Facultés de Médecine et Pharmacie, Université de Bourgogne, 21000 Dijon, France;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marianne Zeller
§Laboratoire de Physiopathologie et Pharmacologie Cardio-Métaboliques, INSERM Unité Mixte de Recherche 866, Facultés de Médecine et Pharmacie, Université de Bourgogne, 21000 Dijon, France;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Aubry Tardivel
¶Department of Biochemistry, University of Lausanne, CH-1066 Epalinges, Switzerland; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pascal Schneider
¶Department of Biochemistry, University of Lausanne, CH-1066 Epalinges, Switzerland; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pal Pacher
‖Laboratory of Physiologic Studies, National Institutes of Health/National Institute on Alcohol Abuse and Alcoholism, Bethesda, MD 20892-9413
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lucas Liaudet
*Department of Intensive Care Medicine, University Hospital Medical Center, University of Lausanne, 1011 Lausanne, Switzerland;
†Department of Clinical Pathophysiology, University Hospital Medical Center, University of Lausanne, 1011 Lausanne, Switzerland;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF + SI
  • PDF
Loading

Abstract

Myocardial infarction (MI) induces a sterile inflammatory response that contributes to adverse cardiac remodeling. The initiating mechanisms of this response remain incompletely defined. We found that necrotic cardiomyocytes released a heat-labile proinflammatory signal activating MAPKs and NF-κB in cardiac fibroblasts, with secondary production of cytokines. This response was abolished in Myd88−/− fibroblasts but was unaffected in nlrp3-deficient fibroblasts. Despite MyD88 dependency, the response was TLR independent, as explored in TLR reporter cells, pointing to a contribution of the IL-1 pathway. Indeed, necrotic cardiomyocytes released IL-1α, but not IL-1β, and the immune activation of cardiac fibroblasts was abrogated by an IL-1R antagonist and an IL-1α–blocking Ab. Moreover, immune responses triggered by necrotic Il1a−/− cardiomyocytes were markedly reduced. In vivo, mice exposed to MI released IL-1α in the plasma, and postischemic inflammation was attenuated in Il1a−/− mice. Thus, our findings identify IL-1α as a crucial early danger signal triggering post-MI inflammation.

Introduction

Myocardial infarction (MI) triggers an inflammatory response aimed at healing the infarct, but it also may foster the process of ventricular remodeling, leading to cardiac dysfunction (1). It is acknowledged that such inflammation is triggered by danger signals (damage-associated molecular patterns [DAMPs]) released by necrotic myocardium and sensed by pattern receptors from the TLR and the NLR families in neighboring cells (2). Although some contribution to these processes has been proposed for TLR2, TLR3, TLR4 (reviewed in Ref. 3), and NLRP3 (4), as well as for DAMPs, such as HMGB1 or S-100 proteins (5), the very proximal signal triggering inflammation in the ischemic heart has not been established. Therefore, the current study was designed to identify the nature of this signal and its sensing mechanisms.

Materials and Methods

Animal experiments were approved by our institutional review board (authorizations 2477, 2484, 2664).

Mice, cells, and treatments

Wild-type (WT) mice in this study were C57BL6/J (Janvier Labs, Le Genest-Saint-Isle, France). Myd88−/− mice (a gift from Dr. Thierry Roger, Lausanne University), Nlrp3−/− mice (obtained from Prof. Pascal Schneider, Lausanne University), and Il1a−/− mice (obtained from Prof. Yoichiro Iwakura, Tokyo University of Science, Chiba, Japan) were backcrossed to C57BL6/J. Mouse neonatal ventricular cardiomyocytes (CMCs) and cardiac fibroblasts (CFs) were isolated by differential plating and cultured as described (6). Some experiments were done using cells isolated from adult mouse hearts immediately after differential plating and before culture, to separate CMCs from all nonmyoycte cells (NMCs; containing CFs, vascular cells, and some resident macrophages). For all experiments, cells were maintained in modified PBS-glucose buffer (7). Necrosis of cells was done by two cycles of freeze–thaw lysis or by exposure to H2O2 (250 μM, 20 min) and confirmed by propidium iodide staining and troponin release (Troponin T Immunoassay; Roche Diagnostics) (8). Conditioned media (2 ml) were obtained by necrosis of 8 × 105 cells and cleared by centrifugation (10 min, 13,000 rpm, 4°C). Anakinra (Swedish Orphan Biovitrum) and IL-1α–blocking Ab (eBioscience) were used at 0.01–10 μg/ml. Heat inactivation of conditioned media was done by heating for 1 h at 95°C. DNase I (Roche) was used at 10 μg/ml. Salmonella LPS (Sigma) was used at 1 μg/ml.

RNA analyses by real-time PCR

RNA was reversed transcribed, and real-time PCR was performed using standard procedures. Gene expressions were normalized to endogenous controls (Rpl19, Gapdh, or Rps18). The list of oligonucleotides is given in Supplemental Table I.

Cytokines, creatine kinase, and troponin

CCL2/MCP-1, IL-6, and IL-1α were measured by commercial ELISAs (R&D Systems and BioLegend). Plasma creatine kinase (CK) and troponin were assayed using a Cobas 8000 automated analyzer (Roche).

Western immunoblotting

Nuclear and cytosolic proteins were immunoblotted as described (7) using primary Abs against ERK1/2, phospho-ERK1/2, p38, phospho-p38, JNK, phospho-JNK, phospho–c-JUN (Cell Signaling Technology), NF-κB p65 (Santa Cruz Biotechnology), IL-1β, TATA-binding protein (Abcam), and tubulin (Sigma).

Cardiac myeloperoxidase activity

Myeloperoxidase (MPO) was measured in myocardial extracts using tetramethylbenzidine and H2O2, as described (9), and was expressed in mU/mg proteins.

EMSA

Nuclear proteins (10 μg) were incubated with an [α-32P]dATP–labeled NF-κB probe (5′-GGCAGTTGAAGGGGACTTTCCCAGG-3′), and EMSA was performed as described (7).

TLR assay

HEK-293 cell lines overexpressing a given murine TLR protein and an inducible NF-κB reporter gene (HEK-Blue TLR cells assay; InvivoGen, Toulouse, France) were treated with conditioned media from necrotic or living CMCs for 4 h. Specific TLR ligands were used as positive controls. TLR−, TNF-sensitive cells expressing the reporter gene only were used as negative controls.

Mouse MI

Myocardial ischemia (30 min) and reperfusion (2 h) were performed as described (8). At the end of reperfusion, blood and heart were obtained for measurement of cytokines. Area at risk (AAR; in percentage of left ventricle [LV]) and infarct size (in percentage of AAR or LV) were determined using standard Evans blue/triphenyl tetrazolium chloride staining (8).

Data analyses

Statistical analyses were done using GraphPad Prism 6.0 software. The Student t test was used for simple comparisons, and multiple comparisons were done with ANOVA, followed by the Dunnett or Bonferroni post test. A p value < 0.05 was considered statistically significant.

Results and Discussion

In a first series of experiments, we determined whether dying CMCs release one or more factors able to trigger innate immune responses in CFs, which may represent “sentinel cells” to detect CMCs’ damage (10). Mouse neonatal CMCs were killed by H2O2 (8) or by freeze–thaw lysis (11), and necrosis was confirmed by propidium iodide staining and troponin release (Fig. 1A, 1B). CFs exposed to conditioned medium obtained from these necrotic CMCs displayed strong transcriptional activation and release of the chemokine CCL2 and the cytokine IL-6 (Fig. 1C–E), associated with the activation of ERK, JNK, p38, NF-κB, and AP-1 (Fig. 1F–H). Because nucleic acids and proteins are two major families of DAMPs (5), we evaluated whether the proinflammatory activity of CMCs would be altered by treatment with DNase or by heating to denaturate proteins. The stimulated transcription of Ccl2 and Il6 was unaffected by DNase but was eliminated by heating (Fig. 2A, 2B), supporting a protein origin of the DAMP in the medium. These findings indicate that one or more soluble, heat-sensitive DAMPs released by necrotic CMCs promote an immediate, reflex, innate immune response in CFs that could represent a primary source of inflammatory cytokines during MI.

FIGURE 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 1.

Conditioned medium from necrotic CMCs triggers innate immune responses in CFs in vitro. CMC necrosis [(A) nuclear PI staining, (B) troponin T release) induced by H2O2 (250 μM, 20 min) or freeze–thaw (FT). CMCs in culture medium or in PBS-glucose (PBS-G) served as controls (n = 3–5 per conditions). mRNA of Ccl2 and Il6 in CFs exposed to conditioned medium from CMCs killed by H2O2 (CM-H2O2) (C) or conditioned medium obtained by freeze–thaw (CM-FT) (D) (n = 3–7). CFs in PBS-G for 4 h served as controls. (E) MCP-1 and IL-6 release by CFs exposed (8 h) to CM-FT or PBS-G (n = 4). (F) Phosphorylation of ERK, JNK, and p38. (G) Cytoplasmic/nuclear NF-κB p65 and nuclear phospho–c-Jun. (H) NF-κB DNA binding activity (EMSA) in CFs exposed to CM-FT. Tubulin and TBP (TATA-binding protein) were used as loading control in (F) and (G). LPS (1 μg/ml, 60 min) was a positive control in (G) and (H). Data are representative of at least three independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001. U, untreated.

FIGURE 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 2.

Necrotic CMCs release a heat-sensitive DAMP, triggering MyD88-dependent and NLRP3- and TLR-independent signaling pathways in CFs. Ccl2 and Il6 mRNA in CFs exposed (4 h) to conditioned medium obtained by freeze–thaw (CM-FT) (A), with or without DNase I or heat inactivation (HI) (B). CFs in PBS-glucose (PBS-G, 4 h) served as controls (n = 3). Ccl2 and Il6 mRNA in WT and Myd88−/− CFs (C) or WT and Nlrp3−/− CFs (D) stimulated for 1–4 h with CM-FT (n = 3–4). (E) HEK-TLR assay in response to TLR agonists or to conditioned medium obtained from live (CM-Ctl) or necrotic (CM-FT) CMCs (n = 2). *p < 0.05, **p < 0.01, ***p < 0.001.

Recent studies indicated that TLR2, TLR3, TLR4 (3), and NLRP3 (4) participate in the cardiac response to ischemia. To explore the role of TLRs or NLRP3 in our model, we examined the response of CFs deficient either in the TLR adapter MyD88 or in Nlrp3 to necrotic CMCs. Transcriptional activation of Ccl2 and Il6 was suppressed in Myd88−/− CFs (Fig. 2C), suggesting an instrumental role for a TLR-mediated process, consistent with previous findings implicating MyD88 in post-MI inflammation (12). In contrast, Nlrp3 deficiency did not have a significant influence (Fig. 2D), arguing against a role for this receptor in the early detection of necrotic CMCs by CFs. This is at variance with a recent study reporting NLRP3 activation in CFs 3 d after MI (4), suggesting that NLRP3 engagement is a delayed, but not immediate, event in the post-MI immune response.

To explore further the role of TLRs, we examined the proinflammatory activity of conditioned medium in TLR-deficient HEK 293 reporter cells selectively transfected with several TLR family members (with the exception of TLR1 and TLR6, which are expressed at low levels in native HEK 293 cells). Unexpectedly, conditioned medium did not activate any of the TLR-transfected cells (Fig. 2E), implicating the participation of an alternative MyD88-dependent signaling cascade in CFs. In addition to TLRs, MyD88 is a crucial adapter downstream of IL-R1 that is primarily activated by one of the two isoforms of IL-1: IL-1α and IL-1β (13). IL-1α is present in various cell types as a fully active cytoplasmic precursor, whereas IL-1β is present as a precursor activated upon proteolytic processing (13). In the heart, the relative expression of the two ligands within the different cell populations is unknown. We found that IL-1α was strongly expressed in CMCs, whereas it was not detected in CFs and was only weakly detected in the whole population of NMCs (Fig. 3A–D), supporting that cardiac IL-1α expression is mainly restricted to CMCs. In contrast, both CMCs and CFs expressed IL-1β mRNA (Fig. 3E), as well as the IL-1β precursor, but neither cell type displayed detectable levels of mature IL-1β, even when stimulated with LPS, which enhanced pro–IL-1β expression (Fig. 3F, 3G). CFs were able to secrete IL-1β when costimulated with LPS and nigericin, an NLRP3 activator, but did not do so when exposed to conditioned medium from necrotic CMCs (Fig. 3G), which is an additional indication that CFs do not detect CMC-derived signals via NLRP3.

FIGURE 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 3.

IL-1α is a major alarmin specifically released by necrotic CMCs. Il1a mRNA (A) and IL-1α protein (B) in neonatal CMCs (n = 3) and CFs (n = 3). (C) IL-1α in conditioned medium obtained by freeze–thaw (CM-FT) obtained from necrotic CMCs or necrotic CFs (n = 3). (D) IL-1α in adult CMCs and cardiac NMCs (n = 4). (E) Il1b mRNA in CMCs and CFs (n = 3). (F) Pro–IL-1β and mature IL-1β (p17) in total cell lysates from CMCs that were either left untreated (Ctrl) or stimulated with LPS (100 ng/ml, 18 h), and in conditioned medium from necrotic CMCs obtained by freeze–thaw (CM-FT). Supernatants of bone marrow macrophages (BMMs) stimulated for (18 h) with LPS (100 ng/ml) and nigericin (Nig, 5 μM) were used as positive control (n = 3). (G) Pro–IL-1β and mature IL-1β in total cell lysates from CFs that were either left untreated (Ctrl) or stimulated (18 h) with LPS (100 ng/ml) or LPS and Nig (5 μM) and in the supernatants of CFs that were left untreated (Untr.) or exposed to CM-FT from necrotic CMCs (1 or 4 h). IL-1β in supernatants from CFs stimulated with LPS and Nig was used as a positive control (n = 3). (H) MCP-1 and IL-6 release by CFs stimulated (4 h) with CM-FT in the presence or absence of anakinra or IL-1α–blocking Ab (0.01–10 μg/ml) (n = 3). Levels of MCP-1 and IL-6 in CM-FT were used as control. (I) Ccl2 and Il6 mRNA in CFs exposed (1, 4 h) to conditioned media (CM-FT) from necrotic CMCs (CMCs→CFs) or necrotic CFs (CFs→CFs) (n = 9). *p < 0.05, **p < 0.01, ***p < 0.001.

These findings prompted us to evaluate whether IL-1α was the DAMP activating CFs in our model. Both the IL-1R antagonist anakinra (14) and an IL-1α–blocking Ab almost completely suppressed the induced expression of CCL2/MCP-1 and IL-6 in CFs (Fig. 3H), implicating IL-1α as a crucial proinflammatory danger signal released by CMCs. This is in line with two previous investigations reporting a role for IL-1α in the neutrophilic inflammation elicited in mice by the implantation of dead cells and extracts of necrotic tissue (15, 16). Such a role for IL-1α was further demonstrated by the striking attenuation of CFs’ immune activation upon stimulation with conditioned medium obtained from CFs (instead of CMCs), which lack IL-1α (Fig. 3I) or from CMCs genetically deficient in IL-1α (Fig. 4A).

FIGURE 4.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 4.

Crucial role for IL-1α in the acute inflammatory response after MI. (A) MCP-1 and IL-6 release by CFs exposed for 4 h to PBS-glucose (PBS-G) or to conditioned medium obtained by freeze–thaw from WT (CM-FT WT) or Il1a−/− (CM-FT Il1a−/−) necrotic CMCs (n = 3). MCP-1 and IL-6 in CM-FT WT and CM-FT Il1a−/− are shown as controls. IL-1α in myocardial tissue (B) and plasma (C) of mice at baseline conditions (Base) and after myocardial ischemia (30 min) and reperfusion (2 h, MIR) or sham ischemia (n = 4–5/group). (D) Myocardial AAR and infarct size (IS) in the percentage of AAR or LV (n = 4/group). Plasma CK (E), troponin (F), plasma IL-6 (G), myocardial MCP-1(H), myocardial IL-6 (I), and MPO activity (J) in WT and Il1a−/− mice at baseline conditions (Base) and after MIR (n = 5–6/group). *p < 0.05, **p < 0.01, ***p < 0.001.

We next sought to determine whether a similar proinflammatory function of IL-1α would take place during MI in vivo, using a murine model of myocardial ischemia and reperfusion (MIR). The expression of IL-1α in the myocardium was detected at similar levels under physiological conditions after sham surgery or after MIR (Fig. 4B), implying that IL-1α is not upregulated by MIR. In contrast, we found that IL-1α was detectable in plasma only after MIR, suggesting its passive release from the necrotic myocardium (Fig. 4C). When MIR was induced in Il1a-null mice, the degree of myocardial injury was not different from WT mice (comparable infarct size and circulating levels of CK and troponin, Fig. 4D–F). Notwithstanding this comparable tissue damage, Il1a−/− mice developed significantly less inflammation following MIR, as shown by a marked reduction in plasma and myocardial cytokines (Fig. 4G–I), as well as suppressed myocardial neutrophil infiltration (evaluated by MPO activity, Fig. 4J).

Our results identify IL-1α, released by dead CMCs and sensed by CFs, as a crucial danger signal in the initiation of sterile inflammation in the infarcted heart. In contrast, our studies do not support a role for TLR- or NLR-dependent mechanisms in such an initiating process, although it must be underscored that our experiments using TLR-expressing HEK 293 cells may be criticized because this represents an artificial in vitro system that cannot rule out a role for potential TLR ligands in the in vivo setting. It is also worth mentioning that our results do not exclude the involvement of additional signals that may be active in vivo, such as the autonomous nervous system, the renin–angiotensin system, and possibly other unidentified signals. Taking these limitations into account, our observations have potential clinical implications, because they provide a conceptual framework for the development of novel pharmacological compounds with a highly specific target in patients with acute MI. Such compounds could prevent adverse ventricular remodeling by interrupting a proximal trigger of excessive inflammatory responses, while leaving innate immune defenses essential for antimicrobial resistance unaltered.

Disclosures

The authors have no financial conflicts of interest.

Acknowledgments

We thank Yoichiro Iwakura for the use of Il1a−/− mice and Alexander K. So (Lausanne University) for the gift of anakinra.

Footnotes

  • This work was supported by the Swiss National Foundation for Scientific Research (Grants 310030_135394/1 to L.L. and 310030_132491 to N.R.-V.), the Muschamp Foundation (to L.L.), and the Intramural Program of the National Institutes of Health/National Institute on Alcohol Abuse and Alcoholism (to P.P.). Breeding of Nlrp3−/− mice was supported by the Institute for Arthritis Research at Lausanne University.

  • The online version of this article contains supplemental material.

  • Abbreviations used in this article:

    AAR
    area at risk
    CF
    cardiac fibroblast
    CK
    creatine kinase
    CMC
    cardiomyocyte
    DAMP
    danger-associated molecular pattern
    LV
    left ventricle
    MI
    myocardial infarction
    MIR
    myocardial ischemia and reperfusion
    MPO
    myeloperoxidase
    NMC
    nonmyocyte cell
    WT
    wild-type.

  • Received August 13, 2014.
  • Accepted November 12, 2014.
  • Copyright © 2015 by The American Association of Immunologists, Inc.

References

  1. ↵
    1. Frangogiannis N. G.
    2014. The inflammatory response in myocardial injury, repair, and remodelling. Nat. Rev. Cardiol. 11: 255–265.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Liaudet L.,
    2. N. Rosenblatt-Velin
    . 2013. Role of innate immunity in cardiac inflammation after myocardial infarction. Front Biosci (Schol Ed) 5: 86–104.
    OpenUrlPubMed
  3. ↵
    1. Christia P.,
    2. N. G. Frangogiannis
    . 2013. Targeting inflammatory pathways in myocardial infarction. Eur. J. Clin. Invest. 43: 986–995.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Sandanger Ø.,
    2. T. Ranheim,
    3. L. E. Vinge,
    4. M. Bliksøen,
    5. K. Alfsnes,
    6. A. V. Finsen,
    7. C. P. Dahl,
    8. E. T. Askevold,
    9. G. Florholmen,
    10. G. Christensen,
    11. et al
    . 2013. The NLRP3 inflammasome is up-regulated in cardiac fibroblasts and mediates myocardial ischaemia-reperfusion injury. Cardiovasc. Res. 99: 164–174.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. de Haan J. J.,
    2. M. B. Smeets,
    3. G. Pasterkamp,
    4. F. Arslan
    . 2013. Danger signals in the initiation of the inflammatory response after myocardial infarction. Mediators Inflamm. 2013: 206039.
    OpenUrlPubMed
  6. ↵
    1. Rosenblatt-Velin N.,
    2. M. G. Lepore,
    3. C. Cartoni,
    4. F. Beermann,
    5. T. Pedrazzini
    . 2005. FGF-2 controls the differentiation of resident cardiac precursors into functional cardiomyocytes. J. Clin. Invest. 115: 1724–1733.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Loukili N.,
    2. N. Rosenblatt-Velin,
    3. J. Rolli,
    4. S. Levrand,
    5. F. Feihl,
    6. B. Waeber,
    7. P. Pacher,
    8. L. Liaudet
    . 2010. Oxidants positively or negatively regulate nuclear factor kappaB in a context-dependent manner. J. Biol. Chem. 285: 15746–15752.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Loukili N.,
    2. N. Rosenblatt-Velin,
    3. J. Li,
    4. S. Clerc,
    5. P. Pacher,
    6. F. Feihl,
    7. B. Waeber,
    8. L. Liaudet
    . 2011. Peroxynitrite induces HMGB1 release by cardiac cells in vitro and HMGB1 upregulation in the infarcted myocardium in vivo. Cardiovasc. Res. 89: 586–594.
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Liaudet L.,
    2. Z. Yang,
    3. E. B. Al-Affar,
    4. C. Szabó
    . 2001. Myocardial ischemic preconditioning in rodents is dependent on poly (ADP-ribose) synthetase. Mol. Med. 7: 406–417.
    OpenUrlPubMed
  10. ↵
    1. Shinde A. V.,
    2. N. G. Frangogiannis
    . 2014. Fibroblasts in myocardial infarction: a role in inflammation and repair. J. Mol. Cell. Cardiol. 70: 74–82.
    OpenUrlCrossRefPubMed
  11. ↵
    1. Iyer S. S.,
    2. W. P. Pulskens,
    3. J. J. Sadler,
    4. L. M. Butter,
    5. G. J. Teske,
    6. T. K. Ulland,
    7. S. C. Eisenbarth,
    8. S. Florquin,
    9. R. A. Flavell,
    10. J. C. Leemans,
    11. F. S. Sutterwala
    . 2009. Necrotic cells trigger a sterile inflammatory response through the Nlrp3 inflammasome. Proc. Natl. Acad. Sci. USA 106: 20388–20393.
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Feng Y.,
    2. H. Zhao,
    3. X. Xu,
    4. E. S. Buys,
    5. M. J. Raher,
    6. J. C. Bopassa,
    7. H. Thibault,
    8. M. Scherrer-Crosbie,
    9. U. Schmidt,
    10. W. Chao
    . 2008. Innate immune adaptor MyD88 mediates neutrophil recruitment and myocardial injury after ischemia-reperfusion in mice. Am. J. Physiol. Heart Circ. Physiol. 295: H1311–H1318.
    OpenUrlAbstract/FREE Full Text
  13. ↵
    1. Garlanda C.,
    2. C. A. Dinarello,
    3. A. Mantovani
    . 2013. The interleukin-1 family: back to the future. Immunity 39: 1003–1018.
    OpenUrlCrossRefPubMed
  14. ↵
    1. So A.,
    2. T. De Smedt,
    3. S. Revaz,
    4. J. Tschopp
    . 2007. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res. Ther. 9: R28.
    OpenUrlCrossRefPubMed
  15. ↵
    1. Chen C. J.,
    2. H. Kono,
    3. D. Golenbock,
    4. G. Reed,
    5. S. Akira,
    6. K. L. Rock
    . 2007. Identification of a key pathway required for the sterile inflammatory response triggered by dying cells. Nat. Med. 13: 851–856.
    OpenUrlCrossRefPubMed
  16. ↵
    1. Rider P.,
    2. Y. Carmi,
    3. O. Guttman,
    4. A. Braiman,
    5. I. Cohen,
    6. E. Voronov,
    7. M. R. White,
    8. C. A. Dinarello,
    9. R. N. Apte
    . 2011. IL-1α and IL-1β recruit different myeloid cells and promote different stages of sterile inflammation. J. Immunol. 187: 4835–4843.
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top

In this issue

The Journal of Immunology: 194 (2)
The Journal of Immunology
Vol. 194, Issue 2
15 Jan 2015
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Advertising (PDF)
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Immunology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Cutting Edge: IL-1α Is a Crucial Danger Signal Triggering Acute Myocardial Inflammation during Myocardial Infarction
(Your Name) has forwarded a page to you from The Journal of Immunology
(Your Name) thought you would like to see this page from the The Journal of Immunology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Cutting Edge: IL-1α Is a Crucial Danger Signal Triggering Acute Myocardial Inflammation during Myocardial Infarction
Jérôme Lugrin, Roumen Parapanov, Nathalie Rosenblatt-Velin, Stéphanie Rignault-Clerc, François Feihl, Bernard Waeber, Olivier Müller, Catherine Vergely, Marianne Zeller, Aubry Tardivel, Pascal Schneider, Pal Pacher, Lucas Liaudet
The Journal of Immunology January 15, 2015, 194 (2) 499-503; DOI: 10.4049/jimmunol.1401948

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Cutting Edge: IL-1α Is a Crucial Danger Signal Triggering Acute Myocardial Inflammation during Myocardial Infarction
Jérôme Lugrin, Roumen Parapanov, Nathalie Rosenblatt-Velin, Stéphanie Rignault-Clerc, François Feihl, Bernard Waeber, Olivier Müller, Catherine Vergely, Marianne Zeller, Aubry Tardivel, Pascal Schneider, Pal Pacher, Lucas Liaudet
The Journal of Immunology January 15, 2015, 194 (2) 499-503; DOI: 10.4049/jimmunol.1401948
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results and Discussion
    • Disclosures
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF + SI
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Cutting Edge: Reduced Adenosine-to-Inosine Editing of Endogenous Alu RNAs in Severe COVID-19 Disease
  • Cutting Edge: EPHB2 Is a Coreceptor for Fungal Recognition and Phosphorylation of Syk in the Dectin-1 Signaling Pathway
  • Cutting Edge: Hypoxia-Induced Ubc9 Promoter Hypermethylation Regulates IL-17 Expression in Ulcerative Colitis
Show more CUTTING EDGE

Similar Articles

Navigate

  • Home
  • Current Issue
  • Next in The JI
  • Archive
  • Brief Reviews
  • Pillars of Immunology
  • Translating Immunology

For Authors

  • Submit a Manuscript
  • Instructions for Authors
  • About the Journal
  • Journal Policies
  • Editors

General Information

  • Advertisers
  • Subscribers
  • Rights and Permissions
  • Accessibility Statement
  • FAR 889
  • Privacy Policy
  • Disclaimer

Journal Services

  • Email Alerts
  • RSS Feeds
  • ImmunoCasts
  • Twitter

Copyright © 2021 by The American Association of Immunologists, Inc.

Print ISSN 0022-1767        Online ISSN 1550-6606